HAVCR2 and neoplasm: Others such as anti-TIGIT or anti-TIM-3, as well as new combinations of ICIs, are being explored to potentiate anti-tumor immune response in different cancer types including solid tumors, multiple myeloma, endometrial cancer, and gastric cancer, among others (NCT02913313, NCT03119428, NCT02817633, NCT03099109, NCT02608268, NCT01968109).